More than half of Americans using GLP-1 drugs now take them to shed pounds, not to manage diabetes, the condition the medications were built to treat.
Quick Take
- A new EY-Parthenon survey finds 54% of U.S. GLP-1 users take the drugs mainly for weight loss.
- That marks the first time weight management has outpaced diabetes and other medical uses combined.
- The shift is reshaping how people shop for food, clothes, and even gym memberships.
- Adoption has grown fast, climbing from under 1% of adults a few years ago to double digits today.
A Majority Now Chases the Scale, Not Blood Sugar
EY-Parthenon’s GLP-1 Consumer Impact Report, released October 22, found that weight-management users now make up the majority of the GLP-1 market in the United States. The firm reports that 54% of current users take the drugs mainly to lose weight, edging out the 46% using them for diabetes or other approved health conditions. That flip is notable because drugs like Ozempic and Wegovy were first approved and marketed as diabetes treatments.
The survey behind the finding was not small or casual. EY-Parthenon polled nearly 15,000 general-population respondents and more than 3,600 current and former GLP-1 users, giving the 54% figure real statistical weight rather than anecdotal buzz. Researchers say the pattern confirms what doctors and pharmacists have been noticing anecdotally for months: patients without diabetes are now driving demand.
From Niche Prescription to Mainstream Lifestyle Drug
The change did not happen overnight. As recently as early 2024, EY-Parthenon estimated that only about half a percent of American adults were using a GLP-1 drug. Within a couple of years, usage climbed into the double digits, fueled by celebrity endorsements, social media buzz, and growing insurance coverage for weight-loss indications. That rapid climb helped tip the balance from diabetes-focused use toward general weight management.
Journalists covering the report describe this as more than a medical footnote. CBS News noted that the drugs, “once dedicated to diabetes patients,” have become the go-to option for people simply trying to drop weight, regardless of whether they have a diabetes diagnosis. That broader appeal has turned a once-specialized pharmaceutical category into something closer to a consumer product.
Why Grocery Aisles and Closets Are Feeling the Effects
EY-Parthenon’s research ties the weight-loss boom directly to changing spending habits. Users are buying less at the grocery store, cutting back on snacks and alcohol, and shifting toward high-protein, lower-calorie foods. Clothing retailers are adjusting too, as shrinking waistlines change what shoppers need from their wardrobes. The report frames this as a broader consumer behavior shift, not just a medical trend confined to doctors’ offices.
Per a new EY-Parthenon survey, 54% of US GLP-1 users now take it mainly for weight loss, the first time that's been the majority. 61% say they eat more protein. Good. If you're on one, stay doctor-supervised, eat your protein, and lift, or you lose muscle you'll want back at 50
— Cross And Crowbar (@CrossAndCrowbar) October 23, 2026
The pattern is not unique to the United States. A separate EY global survey found that 58% of international respondents who obtained GLP-1 prescriptions did so primarily for weight management rather than a diagnosed medical condition. That suggests the American shift toward weight-focused use is part of a wider global trend, not an isolated domestic quirk driven by marketing alone.
What Comes Next for Patients and Policymakers
For conservatives who value personal responsibility and market-driven solutions, the GLP-1 boom raises real questions worth watching closely. Millions of Americans are choosing a pharmaceutical shortcut over diet and exercise, and insurers, employers, and taxpayers may increasingly be asked to foot the bill for lifestyle-driven prescriptions rather than diagnosed disease. That tradeoff deserves honest debate, not knee-jerk cheerleading for every new wonder drug trend. As usage keeps climbing, expect scrutiny over cost, long-term safety, and who ultimately pays for a drug class that started as diabetes care and is now a weight-loss phenomenon reshaping entire industries.
